Mason J.M.,Bristol Haematology and Oncology Center |
Rees G.J.G.,Cancer Unit
Journal of Oncology Pharmacy Practice | Year: 2011
We describe a patient who experienced immediate onset severe thrombocytopenia as part of a hypersensitivity reaction to oxaliplatin, following substantial relatively uncomplicated previous exposure to the drug. We review other reports of acute hematological toxicity from oxaliplatin. We draw attention to the important need for vigilance when patients develop unusual acute symptoms during or shortly after oxaliplatin infusion. © 2011 The Author(s).
Gronberg B.H.,Norwegian University of Science and Technology |
Sundstrom S.,Norwegian University of Science and Technology |
Kaasa S.,Norwegian University of Science and Technology |
Bremnes R.M.,University of Tromso |
And 7 more authors.
European Journal of Cancer | Year: 2010
Aim of the study: To investigate whether patients with severe comorbidity receiving platinum-based chemotherapy for advanced non-small-cell lung cancer (NSCLC) have a shorter overall survival, experience more toxicity or more deterioration of health-related quality of life (HRQoL) than other patients during treatment. Patients and methods: Patients enrolled onto a phase III trial comparing pemetrexed/carboplatin with gemcitabine/carboplatin as first-line therapy of stage IIIB/IV NSCLC were analysed. Eligible patients had performance status 0-2 and adequate kidney/liver/bone-marrow function. Comorbidity was assessed from hospital medical records using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G). Toxicity was graded using the CTCAE v3.0 and the patients reported HRQoL on the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30/LC13. Results: Data from 402 of the 436 of the patients enrolled onto the phase III trial were analysed. The patients with severe comorbidity had similar survival as other patients (6.9 versus 8.1 months; p = .34), similar frequency of neutropenia (48% versus 42%; p = .16), but experienced more neutropenic fevers (12% versus 5%; p = .012) and deaths from neutropenic infections (3% versus 0%; p = .027). They had more thrombocytopenia (46% versus 36%; p = .03), but not more thrombocytopenic bleedings (3% versus 4%; p = .65). In general, the patients with severe comorbidity reported poorer HRQoL, but not significantly more deterioration of HRQoL. Conclusions: The results from our study suggest that patients with advanced NSCLC who have severe co-existing disorders benefit from and tolerate platinum-doublet chemotherapy as well as other patients. They do, however, appear to have a higher risk of acquiring infections when neutropenic. © 2010 Elsevier Ltd. All rights reserved.
Suwanrungruang K.,Cancer Unit |
Wiangnon S.,Khon Kaen University
Asian Pacific Journal of Cancer Prevention | Year: 2015
Background: Colorectal cancer (CRC) is one of the most common cancers worldwide. This study aimed to investigate the risk factors for colorectal cancer in the Thai population. Materials and Methods: A cohort study was carried out in Khon Kaen, Thailand, including 71 cases of histologically confirmed CRC patients among 19,861 participants, aged 30-69 years, who were recruited for a cohort study during the period 1990-2001. Participants were followed-up until 31 December, 2013. To identify factors associated with the incidence of colorectal cancer, hazard ratios were evaluated using Cox proportional hazard regression. Results: No environmental variables could be shown to be significantly related to the risk of CRC. Although in our sample, CRC was more prevalent among males, ex-smokers, and those who drank alcohol beverages = 50 gram/day, but we could not demonstrate significantly associations (HRmale ≥ 1.67, 95% CI, 0.80-3.49, HR ex-smokers = 1.34, 95% CI, 0.52-3.46, and HRalc ≥ 50 = 1.08, 95% CI, 0.43-2.71). Individuals within the sample with a family history of cancer, working hour > 8 hours per day, and current-smokers appeared to have decrease risk of CRC, but again these relationship could not be shown to be significantly associated (HRfam cancer= 0.96, 95% CI, 0.85-1.09, HRwork > 8= 0.84, 95% CI, 0.36-1.93, and HRcurrent-smoker = 0.51, 95% CI, 0.18-1.38). Conclusions: We found no evidence of environmental factors effecting the risk of CRC. There is a need for further research to determine why factors identified risk in other populations appear to not be associated with CRC risk in Thais.
Rees G.J.G.,Cancer Unit
Clinical Oncology | Year: 2010
Patients with good prognosis differentiated thyroid cancer are at risk from over-treatment with radioiodine thyroid remnant ablation. Some with unfavourable localised disease might benefit from an elective second dose. © 2009 The Royal College of Radiologists.
Bye A.,University of Oslo |
Bye A.,Oslo University College |
Jordhoy M.S.,University of Oslo |
Jordhoy M.S.,Cancer Unit |
And 5 more authors.
Supportive Care in Cancer | Year: 2013
Purpose: Cancer cachexia and low energy intake (EI) probably contribute to weight loss in advanced pancreatic cancer (PC). However, little is known about the actual EI in this disease. Aims were to assess EI, weight loss and symptoms during the disease course and investigate associations between symptoms and EI. Methods: Thirty-nine patients (21 males) with advanced PC were consecutively included and followed every 4 weeks until the end of life. A 24-h dietary recall was used to assess EI. The Edmonton Symptom Assessment System (ESAS) and the PC-specific health-related quality of life questionnaire (QLQ-PAN26) were used for symptom assessment. Results: Median age was 62 years (48-88), WHO performance status 1 (0-2) and survival 5 months (1-25). Seventeen (44 %) patients had unresectable cancer, 16 (41 %) metastatic and six (15 %) recurrent disease. Upon inclusion, 37 (95 %) reported weight loss (median 4.0 kg per month). During follow-up, median weight loss per month was <1.0 kg. Forty to 65 % had EI <29 kcal/kg/day (cut-off value for weight maintenance) during the observation period but they did not lose more weight than patients with EI ≥ 29 kcal. Strong negative correlations (r range) were found between EI and pain (0.51-0.61), fatigue (0.54-0.67), oral dryness (0.61-0.64) and loss of appetite (0.53-0.71). Conclusion: In this study, several symptoms influenced EI negatively. Low EI did not completely explain weight loss in this patient group, but careful monitoring and early follow-up of symptoms may be important interventions to reduce weight loss in advanced PC. © 2012 Springer-Verlag.